Sarepta Therapeutics (SRPT) Operating Expenses (2010 - 2026)

Sarepta Therapeutics' Operating Expenses history runs 17 years deep, the most recent figure standing at $372.4 million for Q1 2026.

• In Q1 2026, Operating Expenses fell 64.37% year-over-year to $372.4 million; the TTM figure through Mar 2026 stood at $2.2 billion (down 5.34% YoY), while the FY2025 annual figure was $2.9 billion, up 72.1% from the prior year.
• Operating Expenses for Q1 2026 stood at $372.4 million, down from $854.5 million in the prior quarter.
• The five-year high for Operating Expenses was $1.0 billion in Q1 2025, with the low at $297.7 million in Q1 2022.
• The 5-year median for Operating Expenses is $391.6 million (2023), against an average of $466.7 million.
• The sharpest annual moves came in 2025 and 2026: Operating Expenses soared 176.11% in 2025, then slumped 64.37% in 2026.
• Sarepta Therapeutics' Operating Expenses stood at $365.3 million in 2022, then gained by 1.89% to $372.2 million in 2023, then surged by 33.47% to $496.7 million in 2024, then jumped by 72.03% to $854.5 million in 2025, then tumbled by 56.42% to $372.4 million in 2026.
• Business Quant data shows SRPT's Operating Expenses at $372.4 million in Q1 2026, $854.5 million in Q4 2025, and $502.7 million in Q3 2025.